Zanubrutinib + Rituximab + Lenalidomide + Obinutuzumab
Phase 3Recruiting 1 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Relapsed/Refractory Follicular Lymphoma
Conditions
Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma
Trial Timeline
Mar 10, 2022 → Jun 1, 2030
NCT ID
NCT05100862About Zanubrutinib + Rituximab + Lenalidomide + Obinutuzumab
Zanubrutinib + Rituximab + Lenalidomide + Obinutuzumab is a phase 3 stage product being developed by BeOne Medicines for Relapsed/Refractory Follicular Lymphoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05100862. Target conditions include Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma.
What happened to similar drugs?
0 of 9 similar drugs in Relapsed/Refractory Follicular Lymphoma were approved
Approved (0) Terminated (1) Active (8)
🔄SHR2554; Chidamide analog tablets + SHR2554 analog tablets; ChidamideJiangsu Hengrui MedicinePhase 3
🔄Axicabtagene Ciloleucel + Platinum-containing Salvage Chemotherapy + Cyclophosphamide + FludarabineGilead SciencesPhase 3
Hype Score Breakdown
Clinical
17
Activity
15
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05100862 | Phase 3 | Recruiting |
Competing Products
20 competing products in Relapsed/Refractory Follicular Lymphoma